Update on pharmacotherapy for treatment of opioid use disorder
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Opioid Use Disorder (OUD) is a significant public health concern, negatively impacting the medical, psychological, and social domains of an individual's life as well as creating substantial burdens for society. Effective treatment interventions are necessary for reduction of OUD and its consequences. Pharmacotherapy represents a central component of management. Areas covered: This review focuses on pharmacologic strategies for OUD treatment, discussing both primary as well as adjunctive therapy modalities. We will discuss both medications used during detoxification to treat withdrawal, as well as those used as maintenance therapy. Detox medications include alpha-2 adrenergic agonists, such as clonidine, as well as the μ-opioid agonist, methadone, and the μ-opioid partial agonist, buprenorphine. Opioid maintenance treatment (OMT) is also discussed, focusing on those medications meant to substitute abused opioids and includes the agonists, methadone and buprenorphine, as well as supervised intravenous heroin, and opioid antagonist, naltrexone. Expert opinion: Medication therapy for treatment of OUD has demonstrated efficacy and is of great clinical benefit. While agonist treatment with methadone or buprenorphine remains the gold standard, there is an important place for use of long-acting antagonist therapy with naltrexone. Continued investigation into treatment paradigms and behavioral platforms which optimize medication therapy is most needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505409 · Cited by 315
Medical safety and side effects of methadone in tolerant individuals
Kreek, M. J. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220060039009 · Cited by 247
Hulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.130 · Cited by 135
Withdrawal From Methadone Maintenance: Rate of Withdrawal and Expectation
Senay, E. C. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770150119014 · Cited by 117
Buprenorphine tapering schedule and illicit opioid use
Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., et al. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02455.x · Cited by 112
Kowalczyk, W. J., Phillips, K. A., Jobes, M. L., Kennedy, A. P., Ghitza, U. E., Agage, D. A., Schmittner, J. P., Epstein, D. H., & Preston, K. L. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14081014 · Cited by 101
Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial
Kun⊘e, N., Lobmaier, P., Vederhus, J. K., Hjerkinn, B., Hegstad, S., Gossop, M., Kristensen, Ø., & Waal, H. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.055319 · Cited by 88
Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03424.x · Cited by 77
Bigelow, G. E., Preston, K. L., Schmittner, J., Dong, Q., & Gastfriend, D. R. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.018 · Cited by 47
Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone
Hulse, G. K., Ngo, H. T. T., & Tait, R. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.003 · Cited by 37
Cited by
Ma, J., Bao, Y.-P., Wang, R.-J., Su, M.-F., Liu, M.-X., Li, J.-Q., Degenhardt, L., Farrell, M., Blow, F. C., Ilgen, M., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0094-5 · Cited by 396
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Kosten, T. R., & Baxter, L. E. (2019) · The American Journal on Addictions · doi:10.1111/ajad.12862 · Cited by 235
“Their anti-adrenergic action through autoreceptor feedback inhibition specifically targets the constellation of symptoms generated by opioid withdrawal-induced noradrenergic hyperactivity.(23) In a 2016 meta-analysis, Gowing et al.”
BackgroundInfluentialSelf-citationLevin, F. R., Mariani, J. J., Pavlicova, M., Choi, C. J., Mahony, A. L., Brooks, D. J., Bisaga, A., Dakwar, E., Carpenter, K. M., Naqvi, N., et al. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107700 · Cited by 54
“However, the present trial shows that this combined pharmacologic approach can meet the high bar of abstinence, as has been the case with effective medications for opioid (Ayanga et al., 2016) and nicotine use disorders (Cahill et al.”
BackgroundStress and opioid use disorder: A systematic review
MacLean, R. R., Armstrong, J. L., & Sofuoglu, M. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.05.034 · Cited by 43
Metadata
- Authors
- Ayanga, D., Shorter, D., & Kosten, T. R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2016-10-20
- Volume
- 17
- Issue
- 17
- Pages
- 2307-2318
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2531840703
- Cited by
- 79
- References
- 12
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.